Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,033.27 +14.88 (+0.30%) Dow
38,022.32 +119.03 (+0.31%) Nasdaq
15,716.19 +110.71 (+0.71%) Bitcoin USD
59,056.14 +2,014.62 (+3.53%) CMC Crypto 200
1,275.77 +5.03 (+0.40%)
NovoCure Limited (NVCR)
| Previous close | 12.74 |
| Open | 13.39 |
| Bid | 12.90 x 100 |
| Ask | 13.06 x 100 |
| Day's range | 12.17 - 13.45 |
| 52-week range | 10.87 - 83.60 |
| Volume | |
| Avg. volume | 1,289,957 |
| Market cap | 1.399B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.95 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.33 |
GuruFocus.comNovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
Comprehensive Analysis of NovoCure's First Quarter Financial Performance
ZacksNovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s
